BioMarin Released Five-Year Pompe Disease Trial Data
The study confirmed that Pombiliti and Opfolda therapy maintained respiratory function in 82 participants.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Do you believe long-term clinical data is sufficient to prove medical therapies benefit patients?
BioMarin presented five-year clinical trial results showing that the combination therapy Pombiliti and Opfolda helps patients with late-onset Pompe disease maintain walking distance. The data, which includes patients both new to and experienced with enzyme replacement therapy, showed stable respiratory function throughout the study period.
Why it matters
Late-onset Pompe disease leads to progressive muscle weakness that deteriorates over time. Long-term treatment stability is a critical goal for patients managing this chronic condition.
The clinical trial followed 82 patients for five years to assess the efficacy of Pombiliti and Opfolda. Investigators found no new safety signals during the evaluation period for participants new to or previously treated with enzyme replacement therapy.
The players
BioMarin
This biotechnology company focuses on developing and commercializing therapies for rare genetic diseases.
Amicus Therapeutics
This company specializes in the discovery and development of medicines for rare metabolic diseases and was acquired by BioMarin.
World Muscle Society
This international medical organization hosts an annual congress to share research on neuromuscular disorders.
The details
Presented at the 31st annual Congress of the World Muscle Society, the data demonstrates that the therapy enables patients to sustain their walking distance and maintain respiratory health. These findings build on the company's research portfolio following its acquisition of Amicus Therapeutics.
Timeline
December: BioMarin acquired Amicus Therapeutics.
October 2, 2026: BioMarin released the five-year clinical trial data.
The Big Picture
This study release follows the presentation schedule established by the 31st annual Congress of the World Muscle Society, which provides a standard forum for validating long-term outcomes in rare disease research. These results suggest a paradigm shift in managing chronic neuromuscular stability through long-term combination therapies.
Patients with late-onset Pompe disease may see expanded long-term treatment options that provide more consistent symptom management. This data helps clinicians refine treatment plans to better preserve mobility and breathing function over several years.
The takeaway
Long-term data is essential for validating the effectiveness of chronic disease management plans. Patients and providers should discuss how these five-year findings might influence current care protocols for neuromuscular conditions.
Further reading
For more information on innovations in the industry, explore our Biotech section.
Live Poll
Do you believe long-term clinical data is sufficient to prove medical therapies benefit patients?
